{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:45:51Z","timestamp":1792075551227,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"DOI":"10.1007\/s40261-026-01598-0","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:15:49Z","timestamp":1792066549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Economic Burden of HDV in Italy: Evaluating the Potential Impact and Effects of Bulevirtide for Chronic HDV Infection"],"prefix":"10.1007","author":[{"given":"Martina","family":"Paoletti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-3798","authenticated-orcid":false,"given":"Andrea","family":"Marcellusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta A.","family":"Kondili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Coco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mecozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mollea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Rock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1598_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","volume":"79","author":"MR Brunetto","year":"2023","unstructured":"Brunetto MR, Ricco G, Negro F, Wedemeyer H, Yurdaydin C, Asselah T, et al. EASL clinical practice guidelines on hepatitis delta virus. J Hepatol. 2023;79:433\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.001.","journal-title":"J Hepatol"},{"key":"1598_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.008.","journal-title":"J Hepatol"},{"key":"1598_CR3","unstructured":"World Health Organization (WHO). Hepatitis D [Internet]. 2025 [cited 2026 Jun 16]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-d. Accessed 16 June 2026."},{"key":"1598_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021550","author":"F Negro","year":"2014","unstructured":"Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring Harb Perspect Med. 2014. https:\/\/doi.org\/10.1101\/cshperspect.a021550.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1598_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/gastro\/goz023","volume":"7","author":"BL Da","year":"2019","unstructured":"Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep. 2019;7:231\u201345. https:\/\/doi.org\/10.1093\/gastro\/goz023.","journal-title":"Gastroenterol Rep"},{"key":"1598_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","volume":"80","author":"Polaris Observatory Collaborators","year":"2024","unstructured":"Polaris Observatory Collaborators. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol. 2024;80:232\u201342. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.043.","journal-title":"J Hepatol"},{"key":"1598_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70242","author":"GP Caviglia","year":"2025","unstructured":"Caviglia GP, Dileo E, Olivero A, Mengozzi G, Ciancio A, Loglio A, et al. The medical impact of hepatitis D virus infection in natives and immigrants: the Italian paradigm. Liver Int. 2025. https:\/\/doi.org\/10.1111\/liv.70242.","journal-title":"Liver Int"},{"key":"1598_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107115","author":"LA Kondili","year":"2024","unstructured":"Kondili LA, Brancaccio G, Tosti ME, Coco B, Quaranta MG, Messina V, et al. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort. Int J Infect Dis. 2024. https:\/\/doi.org\/10.1016\/j.ijid.2024.107115.","journal-title":"Int J Infect Dis"},{"key":"1598_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijid.2023.02.006","volume":"129","author":"G Brancaccio","year":"2023","unstructured":"Brancaccio G, Coco B, Nardi A, Quaranta MG, Tosti ME, Ferrigno L, et al. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: clues from the nationwide PITER and MASTER cohorts toward elimination. Int J Infect Dis. 2023;129:266\u201373. https:\/\/doi.org\/10.1016\/j.ijid.2023.02.006.","journal-title":"Int J Infect Dis"},{"key":"1598_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.3.420","author":"G Fattovich","year":"2000","unstructured":"Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000. https:\/\/doi.org\/10.1136\/gut.46.3.420.","journal-title":"Gut"},{"key":"1598_CR11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-4-437","author":"M Rizzetto","year":"1983","unstructured":"Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Aric\u00f2 S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med. 1983. https:\/\/doi.org\/10.7326\/0003-4819-98-4-437.","journal-title":"Ann Intern Med"},{"key":"1598_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(87)80032-6","author":"G Saracco","year":"1987","unstructured":"Saracco G, Rosina F, Brunetto MR, Amoroso P, Caredda F, Farci P, et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol. 1987. https:\/\/doi.org\/10.1016\/S0168-8278(87)80032-6.","journal-title":"J Hepatol"},{"key":"1598_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1365-2893.2010.01353.x","volume":"17","author":"C Yurdaydin","year":"2010","unstructured":"Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010;17:749\u201356. https:\/\/doi.org\/10.1111\/j.1365-2893.2010.01353.x.","journal-title":"J Viral Hepat"},{"key":"1598_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-013-0365-x","author":"M Noureddin","year":"2014","unstructured":"Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014. https:\/\/doi.org\/10.1007\/s11894-013-0365-x.","journal-title":"Curr Gastroenterol Rep"},{"key":"1598_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/v17081100","volume":"17","author":"AE Bardak","year":"2025","unstructured":"Bardak AE, Begum ON, Gurakar M, Sequeira L, Yildiz E, Hikmet OE, et al. Updates on recent advancements in hepatitis D virus treatment. Viruses. 2025;17:1100.","journal-title":"Viruses"},{"key":"1598_CR16","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"MP Manns","year":"2006","unstructured":"Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350\u20139. https:\/\/doi.org\/10.1136\/gut.2005.076646.","journal-title":"Gut"},{"key":"1598_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","volume":"8","author":"MS Sulkowski","year":"2011","unstructured":"Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212\u201323. https:\/\/doi.org\/10.1038\/nrgastro.2011.21.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1598_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03521-13","author":"S Brichler","year":"2014","unstructured":"Brichler S, Gal FL, Neri-Pinto F, Mansour W, Roulot D, Laperche S, et al. Serological and molecular diagnosis of hepatitis delta virus infection: results of a French national quality control study. J Clin Microbiol. 2014. https:\/\/doi.org\/10.1128\/JCM.03521-13.","journal-title":"J Clin Microbiol"},{"key":"1598_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15389","author":"E Degasperi","year":"2023","unstructured":"Degasperi E, Anolli MP, Lampertico P. Bulevirtide for patients with compensated chronic hepatitis delta: a review. Liver Int. 2023. https:\/\/doi.org\/10.1111\/liv.15389.","journal-title":"Liver Int"},{"key":"1598_CR20","unstructured":"European medicines agency. Hepcludex: EPAR\u2014Medicine overview [Internet]. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/hepcludex-epar-medicine-overview_en.pdf. Accessed 16 June 2026."},{"key":"1598_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(22)00433-0","author":"H Wedemeyer","year":"2022","unstructured":"Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study. J Hepatol. 2022. https:\/\/doi.org\/10.1016\/s0168-8278(22)00433-0.","journal-title":"J Hepatol"},{"key":"1598_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/nejmoa2213429","volume":"389","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389:22\u201332. https:\/\/doi.org\/10.1056\/nejmoa2213429.","journal-title":"N Engl J Med"},{"key":"1598_CR23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i47.111637","author":"B Coco","year":"2025","unstructured":"Coco B, Quaranta MG, Tosti ME, Ferrigno L, Brancaccio G, Ciancio A, et al. Sex-based differences in hepatitis delta virus infection: Insights from the Italian PITER hepatitis delta virus cohort. World J Gastroenterol. 2025. https:\/\/doi.org\/10.3748\/wjg.v31.i47.111637.","journal-title":"World J Gastroenterol"},{"key":"1598_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13920","author":"D Razavi-Shearer","year":"2024","unstructured":"Razavi-Shearer D. The economic argument for hepatitis B treatment simplification and expansion. J Viral Hepat. 2024. https:\/\/doi.org\/10.1111\/jvh.13920.","journal-title":"J Viral Hepat"},{"key":"1598_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s41669-023-00466-3","volume":"8","author":"A Kaushik","year":"2024","unstructured":"Kaushik A, Dusheiko G, Kim C, Smith NJ, Kinyik-Merena C, Di Tanna GL, et al. Understanding the natural history of chronic hepatitis D: proposal of a model for cost-effectiveness studies. PharmacoEcon Open. 2024;8:333\u201343. https:\/\/doi.org\/10.1007\/s41669-023-00466-3.","journal-title":"PharmacoEcon Open"},{"key":"1598_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/009286150103500122","author":"S Capri","year":"2000","unstructured":"Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J. 2000. https:\/\/doi.org\/10.1177\/009286150103500122.","journal-title":"Drug Inf J"},{"key":"1598_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/bf03320660","volume":"11","author":"G Fattore","year":"2009","unstructured":"Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEcon Ital Res Artic. 2009;11:83\u201393. https:\/\/doi.org\/10.1007\/bf03320660.","journal-title":"PharmacoEcon Ital Res Artic"},{"key":"1598_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(20)30651-6","author":"H Wedemeyer","year":"2020","unstructured":"Wedemeyer H, Sch\u00f6neweis K, Bogomolov PO, Chulanov V, Stepanova T, Viacheslav M, et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV\/HDV co-infection. J Hepatol. 2020. https:\/\/doi.org\/10.1016\/s0168-8278(20)30651-6.","journal-title":"J Hepatol"},{"key":"1598_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1977795","author":"B Asif","year":"2022","unstructured":"Asif B, Koh C. Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials. Expert Opin Investig Drugs. 2022. https:\/\/doi.org\/10.1080\/13543784.2021.1977795.","journal-title":"Expert Opin Investig Drugs"},{"key":"1598_CR30","first-page":"291","volume":"16","author":"T Asselah","year":"2022","unstructured":"Asselah T, Arama SS, Bogomolov P, Bourliere M, Fontaine H, Gherlan GS, et al. Safety and efficacy of bulevirtide monotherapy and in combination with peginterferon alfa-2a in patients with chronic hepatitis delta: 24 weeks interim data of MYR204 phase 2b study. Hepatol Int. 2022;16:291.","journal-title":"Hepatol Int"},{"key":"1598_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00318-8","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer H, Sch\u00f6neweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023. https:\/\/doi.org\/10.1016\/S1473-3099(22)00318-8.","journal-title":"Lancet Infect Dis"},{"key":"1598_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.002","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013. https:\/\/doi.org\/10.1016\/j.jval.2013.02.002.","journal-title":"Value Health"},{"key":"1598_CR33","unstructured":"Data on file. Gilead Sciences. Systematic literature review and network meta-analysis of pharmacological interventions in hepatitis D NMA Report (v1.0). 2021."},{"key":"1598_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/v14081749","author":"GP Caviglia","year":"2022","unstructured":"Caviglia GP, Ciancio A, Rizzetto M. A review of HDV infection. Viruses. 2022. https:\/\/doi.org\/10.3390\/v14081749.","journal-title":"Viruses"},{"key":"1598_CR35","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jval.2015.05.007","volume":"18","author":"SL Bermingham","year":"2015","unstructured":"Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T.Kennedy P, et al. Cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B in the United Kingdom. Value Health. 2015;18:800\u20139. https:\/\/doi.org\/10.1016\/j.jval.2015.05.007.","journal-title":"Value Health"},{"key":"1598_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-2003-37590","volume":"23","author":"G Fattovich","year":"2003","unstructured":"Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23:47\u201358.","journal-title":"Semin Liver Dis"},{"key":"1598_CR37","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","volume":"35","author":"YS Hsu","year":"2002","unstructured":"Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522\u20137. https:\/\/doi.org\/10.1053\/jhep.2002.33638.","journal-title":"Hepatology"},{"key":"1598_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","volume":"73","author":"D Alfaiate","year":"2020","unstructured":"Alfaiate D, Cl\u00e9ment S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol. 2020;73:533\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.030.","journal-title":"J Hepatol"},{"key":"1598_CR39","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/hep.24370","volume":"54","author":"JL Dienstag","year":"2011","unstructured":"Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54:396\u2013405. https:\/\/doi.org\/10.1002\/hep.24370.","journal-title":"Hepatology"},{"key":"1598_CR40","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1524-4733.2010.00782.x","volume":"13","author":"H Dakin","year":"2010","unstructured":"Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13:922\u201333. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00782.x.","journal-title":"Value Health"},{"key":"1598_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000642","author":"RG Gish","year":"2023","unstructured":"Gish RG, Wong RJ, Di Tanna GL, Kaushik A, Kim C, Smith NJ, et al. Association of hepatitis delta virus with liver morbidity and mortality: a systematic literature review and meta-analysis. Hepatology. 2023. https:\/\/doi.org\/10.1097\/hep.0000000000000642.","journal-title":"Hepatology"},{"key":"1598_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40258-021-00677-x","volume":"20","author":"A Marcellusi","year":"2022","unstructured":"Marcellusi A, Simonelli C, Mennini FS, Kondili LA. Economic consequences of anti-HCV treatment of patients diagnosed through screening in Italy: a prospective modelling analysis. Appl Health Econ Health Policy. 2022;20:133\u201343. https:\/\/doi.org\/10.1007\/s40258-021-00677-x.","journal-title":"Appl Health Econ Health Policy"},{"key":"1598_CR43","unstructured":"Ministero della Salute. DECRETO 25 novembre 2024. Definizione delle tariffe relative all\u2019assistenza specialistica ambulatoriale e protesica. 2024."},{"key":"1598_CR44","unstructured":"Decreto del Ministero della Salute 18 ottobre 2012. Tariffe delle prestazioni di assistenza ospedaliera per acuti, per tipo di ricovero. [Internet]. [cited 2024 May 27]. http:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=28\/01\/2013&redaz=13A00528&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001. Accessed 27 May 2024."},{"key":"1598_CR45","unstructured":"Ministero della Salute. Rapporto annuale sull\u2019attivit\u00e0 di ricovero ospedaliero. DATI SDO 2020. [Internet]. [cited 2024 May 27]. https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_bulevirtide77_allegato.pdf. Accessed 27 May 2024."},{"key":"1598_CR46","doi-asserted-by":"publisher","DOI":"10.35774\/jee2022.01.017","author":"FS Mennini","year":"2022","unstructured":"Mennini FS, Gitto L. Approaches to estimating indirect costs in healthcare: motivations for choice. J Eur Econ. 2022. https:\/\/doi.org\/10.35774\/jee2022.01.017.","journal-title":"J Eur Econ"},{"key":"1598_CR47","unstructured":"Marcellusi A, Viti R, Capone A, Mennini FS. The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model. Eur Rev Med Pharmacol Sci [Internet]. 2015;19:1610\u201320. https:\/\/www.researchgate.net\/publication\/277144377."},{"key":"1598_CR48","unstructured":"Working days calculator in Italy, 2022. [Internet]. [cited 2024 Feb 20]. https:\/\/www.giorni-lavorativi.com\/EN\/. Accessed 20 Feb 2024."},{"key":"1598_CR49","unstructured":"ISTAT, Occupati (migliaia), 2022. [Internet]. [cited 2024 Sep 3]. http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCCV_OCCUPATIT1#. Accessed 3 Sep 2024."},{"key":"1598_CR50","unstructured":"ISTAT, Popolazione residente al 1\u00b0 gennaio, 2022. [Internet]. [cited 2024 Sep 3]. http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCIS_POPRES1. Accessed 3 Sep 2024."},{"key":"1598_CR51","unstructured":"Organisation for Economic Co-operation and Development (OECD). Annual Average Wage, Italy. 2022. [Internet]. [cited 2024 Feb 20]. https:\/\/stats.oecd.org\/index.aspx?DataSetCode=AV_AN_WAGE. Accessed 20 Feb 2024."},{"key":"1598_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06290495","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006. https:\/\/doi.org\/10.1177\/0272989X06290495.","journal-title":"Med Decis Mak"},{"key":"1598_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2024.502241","author":"M Buti","year":"2024","unstructured":"Buti M, Calleja JL, Rodr\u00edguez M\u00c1, Dom\u00ednguez-Hern\u00e1ndez R, Cantero H, Espinoza N, et al. Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D. Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502241.","journal-title":"Gastroenterol Hepatol"},{"key":"1598_CR54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.31055","volume":"72","author":"MI Elsaid","year":"2020","unstructured":"Elsaid MI, Li Y, John T, Narayanan N, Catalano C, Rustgi VK. Economic and health care burdens of hepatitis delta: a study of commercially insured adults in the United States. Hepatology. 2020;72:399\u2013411. https:\/\/doi.org\/10.1002\/hep.31055.","journal-title":"Hepatology"},{"key":"1598_CR55","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/liv.13604","volume":"38","author":"A Wranke","year":"2018","unstructured":"Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, et al. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: the Hepatitis Delta International Network (HDIN). Liver Int. 2018;38:842\u201350. https:\/\/doi.org\/10.1111\/liv.13604.","journal-title":"Liver Int"},{"key":"1598_CR56","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0016-5085(99)70563-9","volume":"117","author":"F Rosina","year":"1999","unstructured":"Rosina F, Conoscitore P, Cuppone R, Rocca G, Giuliani A, Cozzolongo R, et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology. 1999;117:161\u20136.","journal-title":"Gastroenterology"},{"key":"1598_CR57","first-page":"329","volume":"14","author":"L Gheorghe","year":"2005","unstructured":"Gheorghe L, Iacob S, Simionov I, V\u00e3dan R, Gheorghe C, Iacob R, et al. Natural history of compensated viral B and D cirrhosis. Romanian J Gastroenterol. 2005;14:329\u201335.","journal-title":"Romanian J Gastroenterol."},{"key":"1598_CR58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jare.2021.02.009","volume":"33","author":"GP Caviglia","year":"2021","unstructured":"Caviglia GP, Martini S, Ciancio A, Niro GA, Olivero A, Fontana R, et al. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. J Adv Res. 2021;33:183\u20137. https:\/\/doi.org\/10.1016\/j.jare.2021.02.009.","journal-title":"J Adv Res"},{"key":"1598_CR59","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/736452","author":"G Woo","year":"2012","unstructured":"Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DHK, et al. Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol. 2012. https:\/\/doi.org\/10.1155\/2012\/736452.","journal-title":"Can J Gastroenterol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01598-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:03:31Z","timestamp":1792073011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01598-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":59,"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01598-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sara Mollea, Chong Kim and Marvin Rock are employees and stockholders of Gilead. Dr Andrea Marcellusi is an Editorial Board member of Clinical Drug Investigation. Dr Andrea Marcellusi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Loreta A. Kondili is the principal investigator of a research project partially funded by a Gilead Sciences investigator-sponsored research grant awarded to her institution. Daniela Cazzato, Martina Paoletti, Nicola Coppola, Barbara Coco and Alessandra Mecozzi have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analysed in the current study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: Martina Paoletti, Daniela Cazzato, Andrea Marcellusi, Loreta A. Kondili; Acquisition of data: Martina Paoletti, Daniela Cazzato, Andrea Marcellusi, Loreta A. Kondili, Nicola Coppola, Barbara Coco, Alessandra Mecozzi, Sara Mollea, Chong Kim, Marvin Rock; Drafting the manuscript: Martina Paoletti, Daniela Cazzato; Critical revision of the paper for important intellectual content: Andrea Marcellusi, Loreta A. Kondili, Nicola Coppola, Barbara Coco, Alessandra Mecozzi. All authors read and approved the final version and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}